DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin

被引:68
作者
Crul, M [1 ]
van Waardenburg, RCAM
Bocxe, S
van Eijndhoven, MAJ
Pluim, D
Beijnen, JH
Schellens, JHM
机构
[1] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands
[2] St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA
[3] Univ Utrecht, Div Drug Toxicol, Utrecht, Netherlands
关键词
cisplatin; gemcitabine; interaction; DNA repair;
D O I
10.1016/S0006-2952(02)01508-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The influence of DNA repair mechanisms on the interaction between gemcitabine and cisplatin was studied using a panel of Chinese hamster ovary (CHO) cell lines each deficient in one of the following repair pathways: base excision repair (BER), nucleotide excision repair (NER), homologous recombination (HR) and non-homologous end joining (NHEJ). NER and HR are known to be involved in platinum-DNA adduct repair. Single agent experiments demonstrated that each of the repair deficient cell lines had a similar sensitivity towards gemcitabine as the parental cell lines, whereas the NER- and HR-deficient lines showed increased sensitivity towards cisplatin. Furthermore, in the parental cell lines, the administration sequence cisplatin followed by gemcitabine was synergistic, whereas the reversed schedule showed additivity and simultaneous administration revealed antagonistic cytotoxicity. In the repair deficient cell lines, using this synergistic schedule of cisplatin followed by gemcitabine, loss of synergy was observed in the NER- and HR-deficient cell lines. However, the magnitude of the effect in the NER-deficient cells was small. The sensitivity to the combination of cisplatin and gemcitabine shown by the BER- and NHEJ-deficient cell lines did not differ significantly from that of the parental cell line. Cellular accumulation of platinum as well as the formation of GG- and AG-intrastrand adducts in the parental line and in the HR-deficient line were not affected by gemcitabine. In conclusion, our results indicate that BER, NER, HR, and NHEJ are most likely incapable of modulating the cytotoxicity of gemcitabine, and that HR is involved in the synergistic interaction between cisplatin and gemcitabine in our cell system. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:275 / 282
页数:8
相关论文
共 42 条
  • [1] Weekly gemcitabine with monthly cisplatin: Effective chemotherapy for advanced non-small-cell lung cancer
    Abratt, RP
    Bezwoda, WR
    Goedhals, L
    Hacking, DJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) : 744 - 749
  • [2] Achanta G, 2001, CANCER RES, V61, P8723
  • [3] 2'-DEOXY-2'-METHYLENECYTIDINE AND 2'-DEOXY-2',2'-DIFLUOROCYTIDINE 5'-DIPHOSPHATES - POTENT MECHANISM-BASED INHIBITORS OF RIBONUCLEOTIDE REDUCTASE
    BAKER, CH
    BANZON, J
    BOLLINGER, JM
    STUBBE, J
    SAMANO, V
    ROBINS, MJ
    LIPPERT, B
    JARVI, E
    RESVICK, R
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (06) : 1879 - 1884
  • [4] Bergman AM, 1996, CLIN CANCER RES, V2, P521
  • [5] BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
  • [6] A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix
    Burnett, AF
    Roman, LD
    Garcia, AA
    Muderspach, LI
    Brader, KR
    Morrow, CP
    [J]. GYNECOLOGIC ONCOLOGY, 2000, 76 (01) : 63 - 66
  • [7] GENERALIZED EQUATIONS FOR THE ANALYSIS OF INHIBITIONS OF MICHAELIS-MENTEN AND HIGHER-ORDER KINETIC SYSTEMS WITH 2 OR MORE MUTUALLY EXCLUSIVE AND NON-EXCLUSIVE INHIBITORS
    CHOU, TC
    TALALAY, P
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1981, 115 (01): : 207 - 216
  • [8] COMPUTERIZED QUANTITATION OF SYNERGISM AND ANTAGONISM OF TAXOL, TOPOTECAN, AND CISPLATIN AGAINST HUMAN TERATOCARCINOMA CELL-GROWTH - A RATIONAL APPROACH TO CLINICAL PROTOCOL DESIGN
    CHOU, TC
    MOTZER, RJ
    TONG, YZ
    BOSL, GJ
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (20): : 1517 - 1524
  • [9] Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study
    Crino, L
    Scagliotti, G
    Marangolo, M
    Figoli, F
    Clerici, M
    DeMarinis, F
    Salvati, F
    Cruciani, G
    Dogliotti, L
    Pucci, F
    Paccagnella, A
    Adamo, V
    Altavilla, G
    Incoronato, P
    Trippetti, M
    Mosconi, AM
    Santucci, A
    Sorbolini, S
    Oliva, C
    Tonato, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) : 297 - 303
  • [10] Cisplatin resistance and DNA repair
    Crul, M
    Schellens, JHM
    Beijnen, JH
    Maliepaard, M
    [J]. CANCER TREATMENT REVIEWS, 1997, 23 (5-6) : 341 - 366